Search results
ACC 2026 Late-Breaking Science Collection
Video Series
Added:
7 months ago
Source:
Radcliffe Cardiology
According to European Society of Cardiology (ESC) guidelines, a systematic search for diagnostic clues, or ‘red flags’ (RFs), is recommended in patients with hypertrophic cardiomyopathy (HCM) to help tailor disease management. A new study published in the European Heart Journal has investigated the prevalence and clinical significance of these RFs across different HCM phenotypes and clinical…
View more
Added:
1 month ago
Source:
Cardiac Failure Review Journal
Delays in diagnosis and treatment for patients with suspected heart failure (HF) in the community can lead to preventable hospitalisations and deaths. A new modelling study by Dr Kieran Docherty and colleagues suggests that early initiation of disease-modifying therapies in select patients at the time of an elevated natriuretic peptide test could significantly reduce these adverse outcomes…
View more
‘Residual Congestion’ in HF
Author(s):
Aleksandra Gasecka
,
Aleksander Siniarski
Added:
1 year ago
Review Article
Author(s):
Clara Bonanad Lozano
,
Anjay Rastogi
Added:
1 year ago
Dr Anjay Rastogi (David Geffen School of Medicine UCLA, US) and Dr Clara Bonanad (University Clinical Hospital of Valencia, ES) discuss the evolving management strategies of hyperkalaemia in heart failure and chronic kidney disease, in this short video series. In this three part discussion they cover the most recent guidelines from ACC, ESC and KDIGO, real-world evidence from the recent ZORA…
View more
Added:
1 year ago
Source:
Heart Failure 2024
Heart Failure Congress 2024 has unveiled 8 Late-breaking trial sessions for 2024.Heart Failure 2024 will take place at the Lisbon Congress Center in May. Access the full Programme here.For quick and practical summaries of the late-breaking trials, watch our 5-minute Expert Interviews conducted with the investigators, and keep up to date with our Late-Breaker Discussions with Dr Van Spall.Late…
View more
Mineralocorticoid Receptor Antagonists in Heart Failure
Author(s):
Rishi Sethi
,
Pravesh Vishwakarma
,
Akshyaya Pradhan
Added:
1 year ago
Review Article
Author(s):
Added:
5 months ago
AHA Scientific Sessions 2025 - Dr Sarah Cuddy (Brigham and Women's Hospital, US) joins us to discuss the role of non-disease modifying treatments including SGLT2 inhibitors, mineralocorticoid receptor antagonists, GLP-1 receptor agonists, and implantable hemodynamic monitors in cardiac amyloidosis, and what this means for managing heart failure in this unique patient population.Interview…
View more
Author(s):
Clyde W Yancy
Added:
4 months ago
AHA Scientific Sessions 2025 - Dr Clyde Yancy (Northwestern University, US) joins us to explore the future trajectory of heart failure management, examining how prevention strategies, precision medicine approaches, and the evolving responsibilities of cardiologists are reshaping patient outcomes.Interview Questions:Looking at the current state of heart failure management, what do you see as the…
View more